182 related articles for article (PubMed ID: 32299907)
1. RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.
Kellaway SG; Keane P; Kennett E; Bonifer C
Haematologica; 2021 Jun; 106(6):1569-1580. PubMed ID: 32299907
[TBL] [Abstract][Full Text] [Related]
2. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
[TBL] [Abstract][Full Text] [Related]
3. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
Tokita K; Maki K; Mitani K
Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
[TBL] [Abstract][Full Text] [Related]
4. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
Loke J; Assi SA; Imperato MR; Ptasinska A; Cauchy P; Grabovska Y; Soria NM; Raghavan M; Delwel HR; Cockerill PN; Heidenreich O; Bonifer C
Cell Rep; 2017 May; 19(8):1654-1668. PubMed ID: 28538183
[TBL] [Abstract][Full Text] [Related]
5. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
6. Role of the RUNX1-EVI1 fusion gene in leukemogenesis.
Maki K; Yamagata T; Mitani K
Cancer Sci; 2008 Oct; 99(10):1878-83. PubMed ID: 19016745
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
8. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
[TBL] [Abstract][Full Text] [Related]
9. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
10. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
11. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
12. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
13. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.
Matsuura S; Komeno Y; Stevenson KE; Biggs JR; Lam K; Tang T; Lo MC; Cong X; Yan M; Neuberg DS; Zhang DE
Blood; 2012 Nov; 120(19):4028-37. PubMed ID: 22919028
[TBL] [Abstract][Full Text] [Related]
14. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
15. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
[TBL] [Abstract][Full Text] [Related]
16. Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells.
Nafria M; Keane P; Ng ES; Stanley EG; Elefanty AG; Bonifer C
Cell Rep; 2020 May; 31(8):107691. PubMed ID: 32460028
[TBL] [Abstract][Full Text] [Related]
17. MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.
Kohrs N; Kolodziej S; Kuvardina ON; Herglotz J; Yillah J; Herkt S; Piechatzek A; Salinas Riester G; Lingner T; Wichmann C; Bonig H; Seifried E; Platzbecker U; Medyouf H; Grez M; Lausen J
PLoS Genet; 2016 Mar; 12(3):e1005946. PubMed ID: 26990877
[TBL] [Abstract][Full Text] [Related]
18. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
19. t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming.
Kellaway S; Chin PS; Barneh F; Bonifer C; Heidenreich O
Cells; 2020 Dec; 9(12):. PubMed ID: 33322186
[TBL] [Abstract][Full Text] [Related]
20. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
